Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Propiverine Dose-Escalation in Children with OAB
NCT00795925Phase 2Completed
- Sponsor
- APOGEPHA
- Start
- Oct 2004
- Modality
- Small Molecules
01
Overview
Phase 2, open-label trial of propiverine in overactive bladder (OAB) (3 arms), sponsored by APOGEPHA. Primary endpoints: Trough Plasma Concentration, Maximum Plasma Concentration and 2 more. Started Oct 2004; status: completed.
02
Drugs
propiverine
03
Conditions
overactive bladder (OAB)
Beyond the preview
Go deeper on NCT00795925.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00795925.